English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Midazolam delivered by continuous rate infusion (CRI) might be effective in dogs with cluster seizures (CS) or status epilepticus (SE).    Objective  To describe the use and safety of midazolam CRI in dogs with CS or SE.    Animals  One‐hundred six client‐owned dogs presenting to a veterinary teaching hospital with CS or SE.    Methods  Retrospective review of medical records for dogs with CS or SE treated with a midazolam CRI.    Results  Seventy‐nine dogs presented with CS and 27 dogs had SE. Seizure control was achieved in 82/106 dogs (77.4%) receiving a midazolam CRI. The median dose associated with seizure control was 0.3 mg/kg/h (range, 0.1‐2.5 mg/kg/h). The median duration of CRI was 25 hours (range, 2‐96 hours). Seizures were controlled in 34/40 dogs (85%) with idiopathic epilepsy, 32/43 dogs (74%) with structural epilepsy, 12/16 dogs (75%) with unknown epilepsy, and 4/7 dogs (57%) with reactive seizures ( P  = .20). Seizure control was achieved in 81% of dogs with CS and 67% in dogs with SE ( P  = .18). Dogs with idiopathic/unknown epilepsy were more likely to survive than those with structural epilepsy (87% vs 63%,  P  = .009). Adverse effects were reported in 24 dogs (22.6%) and were mild in all cases.    Conclusions and Clinical Importance  Midazolam CRI is apparently safe and might be an effective treatment in dogs with CS or SE.

Continuous rate infusion of midazolam as emergent treatment for seizures in dogs